• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>CNS drug reviews >Guanfacine and guanfacine extended release: treatment for ADHD and related disorders.
【24h】

Guanfacine and guanfacine extended release: treatment for ADHD and related disorders.

机译：胍法辛和胍法辛缓释剂：用于多动症和相关疾病的治疗。

获取原文
获取原文并翻译 | 示例
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Guanfacine, an alpha(2A) adrenoceptor agonist, is U.S. Food and Drug Administration (FDA)-approved for the treatment of hypertension in adolescents and adults. It also has been used "off-label" for several years in children as a possible treatment for attention-deficit/hyperactivity disorder (ADHD) and pervasive developmental disorders (PDDs). Small placebo-controlled trials support the use of guanfacine for the treatment of ADHD. There is more limited research on the use of guanfacine in treating hyperactivity occurring in children diagnosed with PDD. Recently, guanfacine extended release (GXR), a once-daily formulation has been manufactured and studied in phase III clinical trials. Based on preliminary scientific presentations, it also appears to be efficacious in improving ADHD in children. The most common adverse effects associated with guanfacine and GXR treatment is sedation. Adverse cardiovascular effects are uncommon, although modest reductions in blood pressure and heart rate are common. If GXR is FDA-approved, it would be the first alpha(2A) adrenoceptor agonist marketed for ADHD.
机译：Guanfacine是一种alpha（2A）肾上腺素受体激动剂，已获得美国食品和药物管理局（FDA）的批准，可用于治疗青少年和成人的高血压。它也已在儿童中“标签外”使用了数年，作为注意力缺陷/多动障碍（ADHD）和广泛性发育障碍（PDD）的可能治疗方法。小型安慰剂对照试验支持胍法辛治疗多动症。关于胍法辛治疗被诊断为PDD的儿童多动症的研究还很少。最近，已制造出每日一次的胍法辛缓释（GXR）制剂，并已在III期临床试验中进行了研究。根据初步的科学表现，它在改善儿童多动症方面似乎也是有效的。与胍法辛和GXR治疗相关的最常见的不良反应是镇静。尽管血压和心率会适度降低，但心血管不良反应并不常见。如果GXR获得FDA批准，它将是第一个针对ADHD上市的alpha（2A）肾上腺素受体激动剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号